Cardiogen

A tetrapeptide bioregulator directed at cardiac tissue, with essentially no independent Western evaluation.

Cardiogen is classified as a short peptide bioregulator. Its current development status is: preclinical / russian clinical use. The published evidence is thin, largely non-independent, or does not address the uses this compound is marketed for.

The Peptide Institute tracks Cardiogen because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.